Literature DB >> 33554093

Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders.

F Atiq1, J L Saes2,3, M C Punt4, K P M van Galen4, R E G Schutgens4, K Meijer5, M H Cnossen6, B A P Laros-Van Gorkom2,3, M Peters7, L Nieuwenhuizen2,8, M J H A Kruip1, J de Meris9, J G van der Bom10,11, F J M van der Meer12, K Fijnvandraat7,13, I C Kruis9, W L van Heerde2,3,14, H C J Eikenboom12,15, Frank W G Leebeek1, S E M Schols2,3.   

Abstract

BACKGROUND: In recent years, more awareness is raised about sex-specific dilemmas in inherited bleeding disorders. However, no large studies have been performed to assess differences in diagnosis, bleeding phenotype and management of men and women with bleeding disorders. Therefore, we investigated sex differences in a large cohort of well-defined patients with autosomal inherited bleeding disorders (von Willebrand disease (VWD), rare bleeding disorders (RBDs) and congenital platelet defects (CPDs)).
METHODS: We included patients from three nationwide cross-sectional studies on VWD, RBDs and CPDs in the Netherlands, respectively the WiN, RBiN and TiN study. In all studies a bleeding score (BS) was obtained, and patients filled in an extensive questionnaire on the management and burden of their disorder.
FINDINGS: We included 1092 patients (834 VWD; 196 RBD; 62 CPD), of whom 665 (60.9%) were women. Women were more often referred because of a bleeding diathesis than men (47.9% vs 36.6%, p = 0.002). Age of first bleeding was similar between men and women, respectively 8.9 ± 13.6 (mean ±sd) years and 10.6 ± 11.3 years (p = 0.075). However, the diagnostic delay, which was defined as time from first bleeding to diagnosis, was longer in women (11.6 ± 16.4 years) than men (7.7 ± 16.6 years, p = 0.002). Similar results were found when patients referred for bleeding were analyzed separately. Of women aging 12 years or older, 469 (77.1%) had received treatment because of sex-specific bleeding.
INTERPRETATION: Women with autosomal inherited bleeding disorders are more often referred for bleeding, have a longer diagnostic delay, and often require treatment because of sex-specific bleeding. FUNDING: The WiN study was supported (in part) by research funding from the Dutch Hemophilia Foundation (Stichting Haemophilia), Shire (Takeda), and CSL Behring (unrestricted grant).
© 2021 The Authors.

Entities:  

Keywords:  Blood platelet disorders; Hemorrhage; Hemorrhagic disorders; Inherited coagulation disorders; Sex characteristics; von Willebrand disease

Year:  2021        PMID: 33554093      PMCID: PMC7848767          DOI: 10.1016/j.eclinm.2021.100726

Source DB:  PubMed          Journal:  EClinicalMedicine        ISSN: 2589-5370


  31 in total

1.  Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease.

Authors:  E M De Wee; H M Knol; E P Mauser-Bunschoten; J G van der Bom; J C J Eikenboom; K Fijnvandraat; A De Goede-Bolder; B Laros-van Gorkom; P F Ypma; S Zweegman; K Meijer; F W G Leebeek
Journal:  Thromb Haemost       Date:  2011-09-22       Impact factor: 5.249

2.  von Willebrand disease and bleeding in women.

Authors:  M V Ragni; F A Bontempo; A C Hassett
Journal:  Haemophilia       Date:  1999-09       Impact factor: 4.287

3.  Bleeding spectrum in children with moderate or severe von Willebrand disease: Relevance of pediatric-specific bleeding.

Authors:  Yvonne V Sanders; Karin Fijnvandraat; Johan Boender; Evelien P Mauser-Bunschoten; Johanna G van der Bom; Joke de Meris; Frans J Smiers; Bernd Granzen; Paul Brons; Rienk Y J Tamminga; Marjon H Cnossen; Frank W G Leebeek
Journal:  Am J Hematol       Date:  2015-11-17       Impact factor: 10.047

4.  Impact of von Willebrand disease on health-related quality of life in a pediatric population.

Authors:  E M de Wee; K Fijnvandraat; A de Goede-Bolder; E P Mauser-Bunschoten; J C J Eikenboom; P P Brons; F J Smiers; R Tamminga; R Oostenbrink; H Raat; J G van der Bom; F W G Leebeek
Journal:  J Thromb Haemost       Date:  2011-03       Impact factor: 5.824

5.  Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders.

Authors:  F Peyvandi; R Palla; M Menegatti; S M Siboni; S Halimeh; B Faeser; H Pergantou; H Platokouki; P Giangrande; K Peerlinck; T Celkan; N Ozdemir; C Bidlingmaier; J Ingerslev; M Giansily-Blaizot; J F Schved; R Gilmore; A Gadisseur; M Benedik-Dolničar; L Kitanovski; D Mikovic; K M Musallam; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2012-04       Impact factor: 5.824

6.  Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management.

Authors:  Flora Peyvandi; Roberta Palla; Marzia Menegatti; Pier Mannuccio Mannucci
Journal:  Semin Thromb Hemost       Date:  2009-07-13       Impact factor: 4.180

7.  Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease.

Authors:  Eva M de Wee; Yvonne V Sanders; Eveline P Mauser-Bunschoten; Johanna G van der Bom; Manon E L Degenaar-Dujardin; Jeroen Eikenboom; Arja de Goede-Bolder; Britta A P Laros-van Gorkom; Karina Meijer; Karly Hamulyák; Marten R Nijziel; Karin Fijnvandraat; Frank W G Leebeek
Journal:  Thromb Haemost       Date:  2012-08-23       Impact factor: 5.249

8.  Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC.

Authors:  Paolo Gresele; Sara Orsini; Patrizia Noris; Emanuela Falcinelli; Marie Christine Alessi; Loredana Bury; Munira Borhany; Cristina Santoro; Ana C Glembotsky; Ana Rosa Cid; Alberto Tosetto; Erica De Candia; Pierre Fontana; Giuseppe Guglielmini; Alessandro Pecci
Journal:  J Thromb Haemost       Date:  2019-12-16       Impact factor: 5.824

9.  Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.

Authors:  Ferdows Atiq; Karina Meijer; Jeroen Eikenboom; Karin Fijnvandraat; Eveline P Mauser-Bunschoten; Karin P M van Galen; Marten R Nijziel; Paula F Ypma; Joke de Meris; Britta A P Laros-van Gorkom; Johanna G van der Bom; Moniek P de Maat; Marjon H Cnossen; Frank W G Leebeek
Journal:  Br J Haematol       Date:  2018-05-16       Impact factor: 6.998

Review 10.  How I manage severe von Willebrand disease.

Authors:  Frank W G Leebeek; Ferdows Atiq
Journal:  Br J Haematol       Date:  2019-09-09       Impact factor: 6.998

View more
  3 in total

1.  Prevalence, burden and treatment effects of vaginal bleeding in women with (suspected) congenital platelet disorders throughout life: a cross-sectional study.

Authors:  Marieke C Punt; Nienke D Ruigrok; Kitty W M Bloemenkamp; Nanda Uitslager; Rolf T Urbanus; Evelyn Groot; Idske C L Kremer Hovinga; Roger E G Schutgens; Karin P M van Galen
Journal:  Br J Haematol       Date:  2021-09-18       Impact factor: 8.615

2.  The Cost of Von Willebrand Disease in Europe: The CVESS Study.

Authors:  George Morgan; Sarah Brighton; Mike Laffan; Jenny Goudemand; Bethany Franks; Alan Finnegan
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

3.  Desmopressin testing in von Willebrand disease: Lowering the burden.

Authors:  Jessica M Heijdra; Ferdows Atiq; Wala Al Arashi; Quincy Kieboom; Esmee Wuijster; Karina Meijer; Marieke J H A Kruip; Frank W G Leebeek; Marjon H Cnossen
Journal:  Res Pract Thromb Haemost       Date:  2022-09-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.